Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferric carboxymaltose for prevention of chemotherapy-associated anaemia in early breast cancer
ACTRN12620001105932Phase 3Withdrawn
- Sponsor
- Breast Cancer Trials
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial in anaemia and breast cancer comparing Ferric carboxymaltose with Standard of care (2 arms). Primary endpoint: Incidence of significant anaemia. Planned start Jun 2023; status: withdrawn.
02
Drugs
ferric carboxymaltose
03
Conditions
anaemiabreast cancer
Beyond the preview
Go deeper on ACTRN12620001105932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620001105932.